{"doi":"10.1016/j.rpth.2023.100177","title":"Detection of tissue factor–positive extracellular vesicles using the ExoView R100 system","abstract":"BackgroundTissue factor (TF) is essential for hemostasis. TF-expressing extracellular vesicles (TF+ EVs) are released in pathological conditions, such as trauma and cancer, and are linked to thrombosis. Detection of TF+ EV antigenically in plasma is challenging due to their low concentration but may be of clinical utility.ObjectivesWe hypthesised that ExoView can allow for direct measurement of TF+ EV in plasma, antigenically.MethodsWe utilized the anti-TF monoclonal antibody 5G9 to capture TF EV onto specialized ExoView chips. This was combined with fluorescent TF+ EV detection using anti-TF monoclonal antibody IIID8-AF647. We measured tumor cell-derived (BxPC-3) TF+ EV and TF+ EVs from plasma derived from whole blood with or without lipopolysaccharide (LPS) stimulation. We used this system to analyze TF+ EVs in 2 relevant clinical cohorts: trauma and ovarian cancer. We compared ExoView results with an EV TF activity assay.ResultsBxPC-3-derived TF+ EVs were identified with ExoView using 5G9 capture with IIID8-AF647 detection. 5G9 capture with IIID8-AF647 detection was significantly higher in LPS+ samples than in LPS samples and correlated with EV TF activity (R2 = 0.28). Trauma patient samples had higher levels of EV TF activity than healthy controls, but activity did not correlate with TF measurements made by ExoView (R2 = 0.15). Samples from patients with ovarian cancer have higher levels of EV TF activity than those from healthy controls, but activity did not correlate with TF measurement by ExoView (R2 = 0.0063).ConclusionTF+ EV measurement is possible in plasma, but the threshold and potential clinical applicability of ExoView R100, in this context, remain to be established.","journal":"Research and Practice in Thrombosis and Haemostasis","year":2023,"id":336256,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9578,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":243108,"name":"Yohei Hisada","orcid":"0000-0001-9157-0524","position":1,"is_corresponding":false},{"id":1066686,"name":"Jon Hazeldine","orcid":"0000-0002-4280-4889","position":2,"is_corresponding":false},{"id":465346,"name":"Victoria Bae‐Jump","orcid":"0000-0001-6778-0951","position":3,"is_corresponding":false},{"id":1067147,"name":"Thomas Luther","orcid":null,"position":4,"is_corresponding":false},{"id":243111,"name":"Nigel Mackman","orcid":"0000-0002-9170-7700","position":5,"is_corresponding":false},{"id":615649,"name":"Paul Harrison","orcid":"0000-0003-4610-8909","position":6,"is_corresponding":false},{"id":1066685,"name":"Joshua Price","orcid":"0000-0001-9950-7992","position":0,"is_corresponding":true}],"reference_count":67,"raw_metadata":null,"created_at":"2026-07-19T01:10:17.243221Z","pmid":"37333992","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}